Every year, dozens of brand-name drugs approach the end of their patent life with billions in annual revenue at stake. […]
Tentative Drug Approvals: The Definitive Generic Entry Forecasting Playbook Read Post »
How the incentive architecture behind pharmaceutical R&D shapes pipeline decisions, drug pricing, access policy, and $2 trillion in annual investment,
Drug Patents vs. Prize Models: The Complete IP Strategy Guide for Pharma Innovation Read Post »
Every year, the pharmaceutical industry discards hundreds of compounds with known safety profiles, established pharmacokinetics, and years of preclinical data.
Drug Repositioning: The Complete IP, Regulatory, and Investment Playbook Read Post »
Executive Summary Pfizer’s management of sildenafil citrate’s loss of exclusivity (LOE) in the United States is the closest thing small-molecule
Viagra’s Generic Cliff: Why It Wasn’t a Free-for-All Read Post »
Why Asia is the New Biosimilar Battleground The Patent Cliff Meets a Demographic Supercycle The most consequential commercial event in
Introduction: The Structural Collapse of the Primary Care Model The pharmaceutical industry is currently navigating a seismic shift, often described
1. The Core Thesis: A $58 Billion Industry Running a $400 Billion Race India’s pharmaceutical sector occupies a paradoxical position
Who this is for: Pharma and biotech IP teams, R&D leads, portfolio managers, and institutional investors tracking the $654 billion
Personalized Medicine Patent Strategy: The Complete IP Playbook for Pharma and Biotech Read Post »
A deep-dive reference for pharma IP teams, ANDA filers, litigation counsel, and institutional investors. Updated 2025. What the Orange Book
Sign in or create a free account to read this DrugPatentWatch article
